

CLAIMS

1. Use of an animal model showing memory deficiency and/or behavioral disorders such as anxiety, in which at least one of the alleles of the p53 gene is not functional, for the screening of molecules capable of exhibiting anxiolytic activity.

2. Use of an animal model as defined in claim 1, for determining the characteristics of a molecule having an anxiolytic activity such as the pharmacodynamics, the pharmacokinetics and the toxicity.

3. Use of an animal model according to claim 1 or 2, characterized in that the two alleles of the p53 gene are not functional.

4. Use of an animal model as defined in claim 1, for the screening of molecules capable of at least partially restoring memory.

5. Use of an animal model as defined in claim 1, for determining the characteristics of a molecule capable of at least partially restoring memory such as the pharmacodynamics, the pharmacokinetics and the toxicity.

6. Use of an animal model according to one of claims 1 to 5, characterized in that the animal is a mouse.

7. Use of an agent for inducing the metabolic pathway of the p53 gene, upstream or downstream of said gene, for the preparation of the medicament intended for the treatment of memory disorders, anxiety disorders and/or neurodegenerative diseases.

8. Use of an agent according to claim 7 in which the induction of the metabolic pathway of the p53 gene is an induction of the expression of a gene activated by the p53 gene.

9. Use of an agent according to claim 7, in which the induction of the metabolic pathway of the p53 gene is an induction of the expression of a gene inhibited by the

007438-01828-001

p53 gene.

10. Use of an agent according to one of claims 7 to 9, characterized in that the said agent has furthermore an anti-tumor activity through the activation of the metabolic pathway of the p53 gene.
- 5

Add A' }

09762248-021301
FILED "8422960

Add
B2
Abstract